Forging new chemistry solutions
for novel antibiotics
At Forge Therapeutics, we are developing novel antibiotics targeting bacterial metalloenzymes.
As bacteria become more and more resistant to conventional antibiotics, common medical procedures such as surgery, chemotherapy, and dialysis become increasingly risky.
Over 700,000 people
worldwide die from antibiotic-resistant infections and estimates indicate that the annual toll could rise to 10 million people by 2050.
More than 2.8 Million
antibiotic-resistant infections occur in the U.S. each year, leading to more than 35,000 deaths.
Every 11 Seconds
someone in U.S. gets an antibiotic-resistant infection and every 15 minutes someone dies.
$20 Billion is estimated
to cost the U.S. each year in antibiotic resistance.
LATEST NEWS & ARTICLES
The $6 Billion Shot at Making New Antibiotics—Before the Old Ones Fail
Antimicrobials cost as much to develop as other drugs, but don’t earn the same returns. Congress could give drugmakers a ...
Forge Therapeutics awarded up to $17.2 million by NIH/NIAID for FG-LpxC, a novel antibiotic to treat antimicrobial resistance (AMR)
San Diego, California, September 29, 2022 – Forge Therapeutics, Inc. (Forge), a biotechnology company developing novel anti-infectives targeting bacterial ...
Forge Therapeutics achieves CARB-X milestone for FG-LpxC LUNG antibiotic program
San Diego, California, September 22, 2021 – Forge Therapeutics, Inc. (Forge), a biotechnology company developing novel anti-infectives targeting bacterial ...
